Histone methylation modification and diabetic kidney disease: Potential molecular mechanisms and therapeutic approaches (Review).

IF 5.7 3区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL International journal of molecular medicine Pub Date : 2024-11-01 Epub Date: 2024-09-20 DOI:10.3892/ijmm.2024.5428
Peng Qu, Lanfang Li, Qi Jin, Donghai Liu, Yuan Qiao, Yijia Zhang, Qiuyue Sun, Shuman Ran, Zecheng Li, Tongtong Liu, Liang Peng
{"title":"Histone methylation modification and diabetic kidney disease: Potential molecular mechanisms and therapeutic approaches (Review).","authors":"Peng Qu, Lanfang Li, Qi Jin, Donghai Liu, Yuan Qiao, Yijia Zhang, Qiuyue Sun, Shuman Ran, Zecheng Li, Tongtong Liu, Liang Peng","doi":"10.3892/ijmm.2024.5428","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end‑stage renal disease, and is characterized by persistent proteinuria and decreased glomerular filtration rate. Despite extensive efforts, the increasing incidence highlights the urgent need for more effective treatments. Histone methylation is a crucial epigenetic modification, and its alteration can destabilize chromatin structure, thereby regulating the transcriptional activity of specific genes. Histone methylation serves a substantial role in the onset and progression of various diseases. In patients with DKD, changes in histone methylation are pivotal in mediating the interactions between genetic and environmental factors. Targeting these modifications shows promise in ameliorating renal histological manifestations, tissue fibrosis and proteinuria, and represents a novel therapeutic frontier with the potential to halt DKD progression. The present review focuses on the alterations in histone methylation during the development of DKD, systematically summarizes its impact on various renal parenchymal cells and underscores the potential of targeted histone methylation modifications in improving DKD outcomes.</p>","PeriodicalId":14086,"journal":{"name":"International journal of molecular medicine","volume":"54 5","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414529/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of molecular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ijmm.2024.5428","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end‑stage renal disease, and is characterized by persistent proteinuria and decreased glomerular filtration rate. Despite extensive efforts, the increasing incidence highlights the urgent need for more effective treatments. Histone methylation is a crucial epigenetic modification, and its alteration can destabilize chromatin structure, thereby regulating the transcriptional activity of specific genes. Histone methylation serves a substantial role in the onset and progression of various diseases. In patients with DKD, changes in histone methylation are pivotal in mediating the interactions between genetic and environmental factors. Targeting these modifications shows promise in ameliorating renal histological manifestations, tissue fibrosis and proteinuria, and represents a novel therapeutic frontier with the potential to halt DKD progression. The present review focuses on the alterations in histone methylation during the development of DKD, systematically summarizes its impact on various renal parenchymal cells and underscores the potential of targeted histone methylation modifications in improving DKD outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
组蛋白甲基化修饰与糖尿病肾病:潜在的分子机制和治疗方法(综述)。
糖尿病肾病(DKD)是慢性肾病和终末期肾病的主要病因,其特点是持续蛋白尿和肾小球滤过率降低。尽管人们做出了大量努力,但糖尿病肾病发病率的不断上升凸显了人们对更有效治疗方法的迫切需求。组蛋白甲基化是一种重要的表观遗传修饰,其改变可破坏染色质结构的稳定性,从而调节特定基因的转录活性。组蛋白甲基化在各种疾病的发生和发展中起着重要作用。在 DKD 患者中,组蛋白甲基化的变化是介导遗传和环境因素相互作用的关键。以这些修饰为靶点有望改善肾脏组织学表现、组织纤维化和蛋白尿,是一个新的治疗前沿,有可能阻止 DKD 的进展。本综述侧重于 DKD 发病过程中组蛋白甲基化的改变,系统总结了其对各种肾实质细胞的影响,并强调了靶向组蛋白甲基化修饰在改善 DKD 预后方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International journal of molecular medicine
International journal of molecular medicine 医学-医学:研究与实验
CiteScore
12.30
自引率
0.00%
发文量
124
审稿时长
3 months
期刊介绍: The main aim of Spandidos Publications is to facilitate scientific communication in a clear, concise and objective manner, while striving to provide prompt publication of original works of high quality. The journals largely concentrate on molecular and experimental medicine, oncology, clinical and experimental cancer treatment and biomedical research. All journals published by Spandidos Publications Ltd. maintain the highest standards of quality, and the members of their Editorial Boards are world-renowned scientists.
期刊最新文献
[Retracted] PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo. Adrenic acid: A promising biomarker and therapeutic target (Review). Role of DNA methylation transferase in urinary system diseases: From basic to clinical perspectives (Review). [Corrigendum] A regulation loop between Nrf1α and MRTF‑A controls migration and invasion in MDA‑MB‑231 breast cancer cells. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1